Andelyn Capabilities Update July 2026: Gene Therapy

Transitioning lentiviral vector (LVV) manufacturing from early feasibility to commercial production requires balancing platform standardization with application-specific flexibility. Because enveloped viral vectors are exceptionally sensitive to processing shear and environmental degradation, scalable downstream workflows must prioritize high step recoveries without compromising viral integrity. Implementing modular manufacturing frameworks allows developers to tailor cell lines, transfection timing, and enhancer chemistry across both adherent and suspension configurations. Integrating optimized clarification filtration, flat-profile tangential flow filtration, and high-efficiency ion-exchange chromatography achieves end-to-end process recoveries exceeding 20% while maintaining tight functional-to-physical titer ratios. Furthermore, validating flexible downstream fill-and-finish formats ensures that high-yield processes seamlessly adapt to diverse clinical demands—ranging from small-volume autologous cell therapies to large-scale allogeneic applications.

Discover how configurable lentiviral platform strategies can de-risk tech transfers and optimize your clinical supply chain.